MANTOVANI, GIOVANNI
 Distribuzione geografica
Continente #
EU - Europa 28.489
NA - Nord America 2.662
AS - Asia 310
SA - Sud America 4
AF - Africa 1
OC - Oceania 1
Totale 31.467
Nazione #
IT - Italia 27.702
US - Stati Uniti d'America 2.646
UA - Ucraina 270
CN - Cina 245
SE - Svezia 193
GB - Regno Unito 83
DE - Germania 81
FI - Finlandia 64
BE - Belgio 38
FR - Francia 26
IN - India 26
SG - Singapore 21
CA - Canada 16
ES - Italia 8
KR - Corea 7
NL - Olanda 7
RU - Federazione Russa 6
IR - Iran 5
JP - Giappone 4
BO - Bolivia 2
IE - Irlanda 2
PT - Portogallo 2
RO - Romania 2
AR - Argentina 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
GR - Grecia 1
HK - Hong Kong 1
KZ - Kazakistan 1
MU - Mauritius 1
PL - Polonia 1
Totale 31.467
Città #
Cagliari 27.542
Fairfield 407
Woodbridge 265
Chandler 231
Ashburn 209
Houston 199
Seattle 190
Nyköping 181
Wilmington 153
Jacksonville 152
Cambridge 151
Ann Arbor 149
Dearborn 64
Boardman 50
Nanjing 49
Boston 45
Brussels 38
Beijing 34
Shanghai 30
Guangzhou 23
Helsinki 22
New York 22
San Diego 22
Pune 21
Changsha 18
London 18
Shenyang 15
Toronto 15
Nanchang 12
Rome 10
Milan 9
Redwood City 9
Tianjin 9
Jiaxing 8
Norwalk 8
Singapore 8
Jinan 7
Orange 7
San Mateo 7
Auburn Hills 6
Kunming 6
Verona 6
Barcelona 5
Brandizzo 5
Hangzhou 5
Hebei 5
Hefei 5
Los Angeles 5
Sassari 5
Augusta 4
Kilburn 4
Mountain View 4
Somma Vesuviana 4
Torino 4
Amsterdam 3
Chicago 3
Detroit 3
Islington 3
Leawood 3
Monmouth Junction 3
Ningbo 3
Salerno 3
Acton 2
Cerignola 2
Chiswick 2
Chuncheon 2
Cosenza 2
Costa Mesa 2
Dublin 2
Fuzhou 2
Harbin 2
Hounslow 2
Manitou Springs 2
Muenster 2
Redmond 2
Reggello 2
San Giorgio in Bosco 2
Santa Cruz 2
Sobrado de Paiva 2
Tonara 2
Valencia 2
Vitulazio 2
Washington 2
Xian 2
Yazd 2
York 2
Zhengzhou 2
Almaty 1
Arcevia 1
Ardabil 1
Ariano Irpino 1
Brno 1
Buenos Aires 1
Calasetta 1
Camaiore 1
Catania 1
Cedar Knolls 1
Central District 1
Chongqing 1
Formia 1
Totale 30.569
Nome #
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.238
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.052
Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches 1.884
Advances in pharmacologic strategies for cancer cachexia 1.699
Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia 1.531
The nutritional risk in oncology: a study of 1,453 cancer outpatients 1.496
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 1.405
null 936
null 819
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial 778
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response 761
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 742
Current medications for cancer cachexia 740
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients 707
null 681
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer 667
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 602
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 601
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2 566
Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer 558
null 529
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy 476
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs 436
Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma 411
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation 387
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes 379
Efficacy, compliance and prognostic significance of a comprehensive geriatric assessment in the geriatric cancer patient = Efficacia, applicabilità e significato prognostico di una valutazione geriatrica multidimensionale nel paziente oncologico anziano 378
Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate 377
Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexial/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 367
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 362
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation 343
Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells of cancer patients 343
Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect 337
Neo-adjuvant organ-preserving chemotherapy in the management of locally advanced oral cavity and oropharynx cancer: A tentative quantitative evaluation of organ preservation and clinical response 335
Role of proinflammatory cytokines and leptin in cancer-related anorexia/cachexia. Metabolic abnormalities and therapeutic approaches = Ruolo delle citochine infiammatorie e della leptina nell'anoressia/cachessia neoplastica. Aspetti metabolici e terapeutici 335
Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients 330
Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 321
Relationships betxween Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions 320
Tumor-associated lymphomonocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokynes 314
Neo-adjuvant (primary) organ-preserving chemotherapy in the management of locally advanced laryngeal carcinoma: Larynx preservation and clinical response 282
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG) 258
Anorexia/Cachexia and oxidative stress in cancer patients = Anoressia/Cachessia e stress ossidativo nei pazienti con cancro 235
Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC 165
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 158
Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer 119
Medroxyprogesterone acetate reduces the In vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients 96
Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies 79
[p55 and p75 subunits of the IL 2 receptor, membrane bound and soluble, in peripheral lymphocytes in patients with solid tumors] 78
Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1α, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies 78
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial 75
Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy 69
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin 67
Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients 61
Immunologic assessment determined by response to IL-2 and immunophenotyping of tumor-infiltrating lymphocytes, of invaded and non invaded lymph nodes and of peripheral blood lymphocytes from twenty-one patients with primary laryngeal cancer 50
Preovulatory human follicular fluid in vitro inhibits interleukin (IL)- 1α, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes 49
[The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage] 46
Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites 43
Evidence that granulosa cells inhibit interleukin-1α and interleukin-2 production from follicular lymphomonocytes 29
Totale 31.580
Categoria #
all - tutte 44.795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.795


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019540 0 0 0 0 0 0 0 0 77 90 183 190
2019/20207.044 471 170 65 154 2.270 1.774 855 286 215 141 175 468
2020/20218.700 336 338 447 2.022 1.861 1.235 831 663 143 335 369 120
2021/20221.351 108 104 90 69 157 83 60 91 120 103 158 208
2022/20232.493 186 235 193 178 175 292 74 478 170 150 214 148
2023/20242.641 252 135 133 277 372 669 396 237 170 0 0 0
Totale 31.580